Calla Lily Secures $880,000 UK Grant to Advance Vaginal Microbiome Drug Delivery Platform
Key Points
- Calla Lily Clinical Care has received a £700,000 (approximately $880,000) Innovate UK grant to expand its Callavid intravaginal delivery platform into live biotherapeutics and probiotics.
- The £1 million FLORA project will improve Lactobacillus delivery, transfer and retention to restore vaginal microbiome health and address bacterial vaginosis recurrence.
- This is Calla Lily's third Innovate UK grant and third funded Callavid application, following progesterone delivery and targeted antibiotic programs.
Calla Lily Clinical Care has received a £700,000 (approximately $880,000) grant from Innovate UK to expand the applications of its Callavid intravaginal drug delivery platform into live biotherapeutics and probiotics for vaginal microbiome health. The funding, awarded through Innovate UK’s Growth Catalyst: Investor Partnerships program, will support a £1 million (approximately $1.26 million) development project combining government funding with private investment. The initiative will focus on adapting Callavid to deliver live biotherapeutic products (LBPs) and beneficial bacteria intended to restore and maintain a healthy vaginal microbiome.
The project, named FLORA (Focused Lactobacillus Optimized Retention and Adhesion), will use Calla Lily’s patented delivery technology to improve the administration, transfer and retention of Lactobacillus species. These bacteria play an important role in maintaining vaginal microbiome balance and protecting against certain infections.
Vaginal dysbiosis, an imbalance in the natural bacterial environment, is commonly associated with bacterial vaginosis (BV). The condition has been linked to increased susceptibility to sexually transmitted infections, including HPV and HIV, as well as pelvic inflammatory disease, pregnancy complications and reduced fertility outcomes.
Current treatment approaches rely heavily on antibiotics, but recurrence remains a significant challenge. According to the company, approximately 58% of women experience a recurrence of bacterial vaginosis within 12 months. Repeated antibiotic treatment also raises concerns about antimicrobial resistance (AMR).
The FLORA program will investigate whether more effective delivery of Lactobacillus-based products could help restore the vaginal microbiome while reducing reliance on repeated antibiotic courses. Calla Lily intends to develop Callavid as an over-the-counter product designed to improve probiotic delivery, retention and colonization. The platform is being developed to address limitations associated with existing vaginal treatment formats, including product leakage, inconsistent dosing and usability challenges.
In addition to adapting the delivery device, the FLORA project will include development of a proprietary laboratory model to assess bacterial colonization and generate data to guide subsequent product development.
The latest award marks Calla Lily’s third Innovate UK grant and the third independently funded therapeutic application of its Callavid platform. Previous programs have focused on progesterone delivery for threatened miscarriage and targeted antibiotic administration designed to minimize effects on the gut microbiome.
The company’s progesterone program is being evaluated in the NIHR-funded FREEDOM clinical trial, which has completed enrollment of 400 patients. The study is assessing 400 mg progesterone delivered through Callavid in patients with luteal phase insufficiency, a condition associated with infertility and miscarriage risk.
Calla Lily has also joined Wellcome Leap’s $50 million Focused Antibiotics program, which is supporting efforts to develop improved antibiotic delivery approaches and address antimicrobial resistance.
Thang Vo-Ta, Co-founder and CEO of Calla Lily Clinical Care, highlights the importance of delivery technology in microbiome-based treatments, emphasizing that beneficial bacteria must reach the appropriate location and remain there to have a meaningful therapeutic effect.
With the FLORA program, Calla Lily is seeking to extend Callavid beyond conventional pharmaceutical delivery into microbiome-based therapies, adding another potential application to its women’s health development portfolio.
Learn more at www.callali.ly.
Total Page Views: 2

















